All In Biotech

Drug Trial Radar · NCT03789006

Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney Transplantation

Efficiency of Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil When Used in Combination With Tacrolimus and Prednisolone in Living Donor Kidney Transplantation

Last checked: Nov 19, 2026Latest source record: Jan 3, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

300

Planned (sponsor's estimate)

Start

Mar 21, 2018

Primary completion

Mar 21, 2022

Study completion Mar 21, 2024

Sponsor

Lead sponsor
University of KhartoumAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Center for Kidney Diseases and Surgery
First posted
Dec 28, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Kidney transplantation is the best available treatment option for patients with end stage renal disease. However, kidney transplantation requires life-long use of immunosuppressive medication. Because of the high cost of these medications we need to carefully evaluate the cost-effectiveness of each drug regimen, especially in low-middle income countries. The objective of this clinical trial is to compare the efficiency and cost of two immunosuppressive protocols after living donor kidney transplantation: (1) antithymocyte globulin, tacrolimus, azathioprine and prednisolone versus (2) basiliximab, tacrolimus, mycophenolate mofetil and prednisolone.

Conditions

  • Kidney Transplant Rejection

Interventions

  • Antithymocyte Immunoglobulin (Rabbit)Drug

    Induction agent for living donor kidney transplantation

  • Interleukin 2 Receptor AntagonistDrug

    Induction agent for living donor kidney transplantation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of acute rejectionTime frame: 6 months post kidney transplant
  2. One year graft survivalTime frame: 1 year post kidney transplant

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Doctor Salma Center for Kidney Diseases

    Khartoum, Sudan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.